Clinical Validation of Artificial Intelligence-Powered PD-L1 Tumor Proportion Score Interpretation for Immune Checkpoint Inhibitor Response Prediction in Non-Small Cell Lung Cancer.

Hyojin Kim Seokhwi KimSangjoon ChoiChanghee Park Seonwook ParkSergio PereiraMinuk MaDonggeun YooKyunghyun PaengWonkyung JungSehhoon Park Chan-Young OckSe-Hoon LeeYoon-La ChoiJin-Haeng Chung

Published in: JCO precision oncology (2024)

PD-L1 TPS assessed by AI analyzer correlates with that of pathologists, with clinical performance also being comparable when referenced to PFS. The AI model can accurately predict tumor response and PFS of ICI in advanced NSCLC via assessment of PD-L1 TPS.

Keyphrases

artificial intelligence
machine learning
big data
deep learning
small cell lung cancer
tyrosine kinase
clinical evaluation